US20230131362A1 - Intraosseous implanted biological sensor - Google Patents
Intraosseous implanted biological sensor Download PDFInfo
- Publication number
- US20230131362A1 US20230131362A1 US17/806,420 US202217806420A US2023131362A1 US 20230131362 A1 US20230131362 A1 US 20230131362A1 US 202217806420 A US202217806420 A US 202217806420A US 2023131362 A1 US2023131362 A1 US 2023131362A1
- Authority
- US
- United States
- Prior art keywords
- sensor
- control unit
- housing
- sensing units
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000011282 treatment Methods 0.000 claims abstract description 24
- 210000001185 bone marrow Anatomy 0.000 claims abstract description 7
- 238000000034 method Methods 0.000 claims abstract description 7
- 229940079593 drug Drugs 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 239000012491 analyte Substances 0.000 claims description 7
- 239000012528 membrane Substances 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 5
- 230000002792 vascular Effects 0.000 claims description 5
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 238000004891 communication Methods 0.000 claims description 3
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 claims description 2
- 229930182837 (R)-adrenaline Natural products 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 102000004877 Insulin Human genes 0.000 claims description 2
- 108090001061 Insulin Proteins 0.000 claims description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 2
- 239000013543 active substance Substances 0.000 claims description 2
- 239000003146 anticoagulant agent Substances 0.000 claims description 2
- 229940127219 anticoagulant drug Drugs 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- UBAZGMLMVVQSCD-UHFFFAOYSA-N carbon dioxide;molecular oxygen Chemical compound O=O.O=C=O UBAZGMLMVVQSCD-UHFFFAOYSA-N 0.000 claims description 2
- 239000000701 coagulant Substances 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 239000007857 degradation product Substances 0.000 claims description 2
- 239000002359 drug metabolite Substances 0.000 claims description 2
- 239000003792 electrolyte Substances 0.000 claims description 2
- 229960005139 epinephrine Drugs 0.000 claims description 2
- 230000002068 genetic effect Effects 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 230000002489 hematologic effect Effects 0.000 claims description 2
- 230000003054 hormonal effect Effects 0.000 claims description 2
- 229940088597 hormone Drugs 0.000 claims description 2
- 239000005556 hormone Substances 0.000 claims description 2
- 229960000890 hydrocortisone Drugs 0.000 claims description 2
- 230000002757 inflammatory effect Effects 0.000 claims description 2
- 229940125396 insulin Drugs 0.000 claims description 2
- 239000003446 ligand Substances 0.000 claims description 2
- 230000002503 metabolic effect Effects 0.000 claims description 2
- 210000004197 pelvis Anatomy 0.000 claims description 2
- 230000000144 pharmacologic effect Effects 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 231100000133 toxic exposure Toxicity 0.000 claims description 2
- 238000012544 monitoring process Methods 0.000 abstract 1
- 238000012545 processing Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 4
- 238000002483 medication Methods 0.000 description 4
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 229940075522 antidotes Drugs 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000007707 calorimetry Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000002032 lab-on-a-chip Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0002—Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network
- A61B5/0004—Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network characterised by the type of physiological signal transmitted
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14503—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue invasive, e.g. introduced into the body by a catheter or needle or using implanted sensors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1455—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
- A61B5/1459—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters invasive, e.g. introduced into the body by a catheter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
- A61B5/4839—Diagnosis combined with treatment in closed-loop systems or methods combined with drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
- A61B5/6846—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive
- A61B5/6867—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive specially adapted to be attached or implanted in a specific body part
- A61B5/6878—Bone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/74—Details of notification to user or communication with user or patient ; user input means
- A61B5/742—Details of notification to user or communication with user or patient ; user input means using visual displays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4845—Toxicology, e.g. by detection of alcohol, drug or toxic products
Definitions
- the invention relates to the field of biological sensors. More particularly, the invention relates to an intraosseous implantable biological sensor.
- Bio sensors are known. However, what is needed is a biological sensor that can be implanted into the bone marrow for long-term to assaying of circulating active and inactive substances which relate to physiologic and pathologic processes.
- the method and system in accordance with the invention monitors analytes in the circulation by providing a biological sensor that is embedded in the bone marrow of a patient and may be self contained within a housing.
- the functional system is entirely embedded within a patient’s body.
- the biological sensor may measure physiological parameters of a patient, including analytes, on a fixed or adjustable schedule.
- the biological sensor includes a control unit having a transmitter and an energy source for providing energy to the control unit.
- the biological sensor may be used to adjust other medical treatments and devices in a closed or semi closed loop mechanism or predict patient treatment.
- the biological sensor includes a membrane that can be used to access component in the biological sensor to replace or replenish them a system by use of a temporary external attachment using a catheter or other delivery device.
- the biological sensor may be easily removed from the implantation site and its component parts removed and/or replaced in whole or in part.
- the housing of the biological sensor may be coated with a biocompatible or inert material or may comprise a biocompatible or inert material.
- the biological sensor may also include an integrated treatment system for providing treatment to a patient based on the data received from the sensing units.
- the treatment system may be implanted in another surgical site or may be external to the patient but connectable to the patient by catheters, tubing and the like for delivery of medications.
- the treatment may be initiated by the control unit immediately upon receiving data from the sensing units or may be varied over time based on data received from the sensing units.
- treatment may be suggested, i.e. on the display of an external computing system, but not activated.
- the biological sensor may also include an embedded energy source and control unit including a transmitter.
- the energy source and/or transmitter are separate from the biological sensor.
- the control unit may be integrated into the biological sensor or may be external to the biological sensor positioned in another part of the body or alternatively external to the body.
- the control unit may adjust the parameters of system and monitor settings by use of wireless command.
- the sensor for measuring analytes in accordance with the invention includes a housing having an interior; a housing control unit positioned within the housing and having a transmitter and a receiver; an energy source positioned within the housing for providing energy to the control unit; one or more sensing units disposed at least partially within the housing and extending from the housing into a bone marrow of a patient; and a membrane covering a part of the housing that is configured to allow access to the interior of the housing.
- the sensor further includes an ancillary control unit located remotely from the sensor and in communication with the housing control unit.
- the ancillary control unit has a display for displaying information received from the sensing units through the housing control unit.
- the housing control unit may receives a signal from the one or more sensing units and transmits to the ancillary control unit.
- the ancillary control unit includes a display and the signal includes patient analyte data that may be displayed on the display.
- the housing control unit is configured to receive a signal from the at least one or more sensing units, the signal including patient analyte data and may transmit instructions to the at least one or more sensing units to measure analytes data on a fixed or adjustable schedule.
- the housing control unit may receive a signal from the at least one or more sensing units and transmit it to the ancillary control unit and the ancillary control unit transmits instructions to the one or more sensing units to adjust the measurement of analytes.
- the ancillary control unit or the housing control unit may also transmit instructions to a treatment system to deliver medications to the patient based on the patient analyte data contained within the signal.
- the treatment system may be housed within the housing or located remotely from a site where the sensor is implanted.
- the one or more sensing units may be removable and replaceable and/or capable of being restored or reconditioned through the housing membrane.
- the sensor includes a replaceable or renewable energy source selected from one or more replaceable batteries or a self generating system which uses a process such as motion or vascular flow, body heat, or chemical reaction.
- FIG. 1 is an illustration depicting a pelvis identifying a location site for implanting the sensor in accordance with the invention.
- FIG. 2 is a schematic diagram of the sensor in accordance with the invention.
- the sensor 10 broadly includes a housing 12 , one or more sensing units 14 , a control unit 16 and an energy source 18 .
- the housing 12 includes a membrane 20 thereon that allows replacement and/or replenishment of individual parts, such as sensing units 14 .
- An ancillary processing device/control unit 22 can also be utilized and may integrated into the sensor or positioned and used at a remote location.
- Sensor 10 may direct automated and semi automated treatment techniques such as closed, and partially closed loop infusions.
- closed, and partially closed loop infusions The insertion into the marrow space allows measurement through small blood channels while allowing the sensor 10 to be fixed directly to tissue.
- the sensor 10 is embedded (implanted) so that the skin and subcutaneous tissues cover it allowing minimal external compromise.
- Sensing units 14 may include optical, enzymatic, calorimetry, thermal, spectroscopy, or “lab on a chip.” A portion of the sensing units 14 are housed within the sensor housing and a portion thereof may project into the bone marrow 26 of a patient. Alternatively, the distal end of the sensing units may be flush with the housing 12 but housing may contain an opening 30 that exposes the sensing units to the bone marrow These may be in a combined modality and other non specified technologies may also be used. The device may measure one or more analytes over various time cycles. These may be fixed or controlled externally by a wireless method to adjust the timing of the sensor 10 .
- Control unit 16 may include a receiver for receiving a signal from the sensing units that includes physiological data of the patient.
- the control unit 16 may also includes a transmitter that may transmit the signal to a remotely located ancillary processing device 22 for analysis.
- the processing device 22 may include a display screen for displaying the analyzed data to monitor the condition of the patient.
- Data generated from the sensing units 14 may alter treatment settings of respirators, dialysis systems, pacemakers, defibrillators and intravenous, intraarterial, interstitial, cerebrospinal and subcutaneous injections and infusions as well as alteration and adjustment of other medical devices or treatments.
- Control unit 16 may include memory having a data base of knowledge including known normative data related to interpreting the analyte data received from the sensing units.
- Control unit 16 receives a signal from the sensing units which contains patient physiological parameters and analyzes the physiological parameters and other data obtained from the sensing units 14 .
- Control unit 16 analyzes the data (i) in isolation as it is received; (ii) in the context of measurement and analysis based on the past history of the patient, which is stored in memory; or (iii) cross-references the patient data in the signal and cross-references it with the known normative data in the database.
- control unit 16 transmit the signal to a remotely located ancillary processing/control unit 22 .
- the processing unit 22 optionally includes a display device 24 for displaying the output.
- the control unit 16 or the ancillary processing unit 22 can also include information related to goal-directed therapies associated with particular disease states for providing suggested goal-directed treatments based on the cross-referencing step and outputs a suggested treatment by transmitting it wirelessly or by wire to a treatment system 28 .
- the treatment system 28 may include one or more medications for delivering the medications to a patient.
- the sensing units 14 could monitor potentially toxic substances such as inhalants or injurious materials allowing rapid treatment, for example antidotes.
- Such treatment could be integrated with a separate embedded structure and could be initiated by a signal from the sensor.
- This treatment component could be embedded in the marrow 26 or another part of the body.
- Energy source 18 may include one or more replaceable batteries or a self generating system which uses a process such as motion or vascular flow, body heat, or chemical reaction. These in combination with other sources known to those of skill in the art may also be used.
- the sensor 10 is configured to measure and record numerous analytes including but not limited to biochemical, hormonal, inflammatory, hematologic, genetic/nucleic acid and physiologic concentrations, vascular pressures, flow rates, pharmacologic concentrations, degradation products, pH, oxygen, carbon dioxide, toxic exposures, metabolic factors such as glucose, lactate, electrolytes; hormones such as cortisol, insulin, epinephrine; drug and drug metabolites; other therapeutic substances such as monoclonal antibodies, ligands, and chemotherapeutic agents; hematologically active substances such coagulants and anticoagulants; DNA, RNA and nucleic acid containing substances.
- the sensor 10 may be implanted by surgical insertion and remain without extension through the skin.
- the area of implantation is pelvic and usually the ileum but not restricted to these sites.
- the housing 12 may comprise biologically inert or biocompatible material such as polymers, stainless steel, silicone and the like.
- the housing membrane 20 is porous so as to allow contact with the marrow circulation without producing inflammation and/or rejection.
- Regeneration of the sensing units 14 could be through injection or insertion of new material through temporary use of a catheter or needle into the device or alternatively extraction of the sensing units and replacement such as in a self contained form.
- the entire sensor may be replaced or individual parts such as the energy source 18 or control unit 16 may be replaced or replenished.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- Surgery (AREA)
- Public Health (AREA)
- Pathology (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Optics & Photonics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Physiology (AREA)
- Computer Networks & Wireless Communication (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
Abstract
A method and system for monitoring analytes in the circulatory system of an individual is provided. A biological sensor is implanted in the bone marrow of a patient and may be self contained within a housing. The biological sensor measures physiological parameters of a patient, including analytes, on a fixed or adjustable schedule. The biological sensor includes a control unit having a transmitter and an energy source for providing energy to the control unit. The biological sensor may be used to adjust other medical treatments and devices in a closed or semi closed loop mechanism and/or predict patient treatment.
Description
- This patent document is a continuation of U.S. Pat. Application No. 16/976,104 filed Aug. 27, 2020, which is a national phase entry of International Application No. PCT/US2019/021559 filed Mar. 11, 2019, which claims priority to U.S. Provisional Pat. Application No. 62/641,737 filed Mar. 12, 2018. The disclosures of the listed applications are fully incorporated into this document by reference.
- The invention relates to the field of biological sensors. More particularly, the invention relates to an intraosseous implantable biological sensor.
- Biological sensors are known. However, what is needed is a biological sensor that can be implanted into the bone marrow for long-term to assaying of circulating active and inactive substances which relate to physiologic and pathologic processes.
- The foregoing need is addresses by the intraosseous implantable biological sensor in accordance with the invention.
- The method and system in accordance with the invention monitors analytes in the circulation by providing a biological sensor that is embedded in the bone marrow of a patient and may be self contained within a housing. The functional system is entirely embedded within a patient’s body. The biological sensor may measure physiological parameters of a patient, including analytes, on a fixed or adjustable schedule.
- The biological sensor includes a control unit having a transmitter and an energy source for providing energy to the control unit. The biological sensor may be used to adjust other medical treatments and devices in a closed or semi closed loop mechanism or predict patient treatment.
- The biological sensor includes a membrane that can be used to access component in the biological sensor to replace or replenish them a system by use of a temporary external attachment using a catheter or other delivery device. The biological sensor may be easily removed from the implantation site and its component parts removed and/or replaced in whole or in part.
- The housing of the biological sensor may be coated with a biocompatible or inert material or may comprise a biocompatible or inert material.
- The biological sensor may also include an integrated treatment system for providing treatment to a patient based on the data received from the sensing units. Alternatively, the treatment system may be implanted in another surgical site or may be external to the patient but connectable to the patient by catheters, tubing and the like for delivery of medications. The treatment may be initiated by the control unit immediately upon receiving data from the sensing units or may be varied over time based on data received from the sensing units. Alternatively, treatment may be suggested, i.e. on the display of an external computing system, but not activated.
- The biological sensor may also include an embedded energy source and control unit including a transmitter. Alternatively, the energy source and/or transmitter are separate from the biological sensor.
- The control unit may be integrated into the biological sensor or may be external to the biological sensor positioned in another part of the body or alternatively external to the body. The control unit may adjust the parameters of system and monitor settings by use of wireless command.
- The sensor for measuring analytes in accordance with the invention includes a housing having an interior; a housing control unit positioned within the housing and having a transmitter and a receiver; an energy source positioned within the housing for providing energy to the control unit; one or more sensing units disposed at least partially within the housing and extending from the housing into a bone marrow of a patient; and a membrane covering a part of the housing that is configured to allow access to the interior of the housing.
- The sensor further includes an ancillary control unit located remotely from the sensor and in communication with the housing control unit. The ancillary control unit has a display for displaying information received from the sensing units through the housing control unit.
- The housing control unit may receives a signal from the one or more sensing units and transmits to the ancillary control unit. The ancillary control unit includes a display and the signal includes patient analyte data that may be displayed on the display.
- The housing control unit is configured to receive a signal from the at least one or more sensing units, the signal including patient analyte data and may transmit instructions to the at least one or more sensing units to measure analytes data on a fixed or adjustable schedule. Alternatively, the housing control unit may receive a signal from the at least one or more sensing units and transmit it to the ancillary control unit and the ancillary control unit transmits instructions to the one or more sensing units to adjust the measurement of analytes. The ancillary control unit or the housing control unit may also transmit instructions to a treatment system to deliver medications to the patient based on the patient analyte data contained within the signal. The treatment system may be housed within the housing or located remotely from a site where the sensor is implanted.
- The one or more sensing units may be removable and replaceable and/or capable of being restored or reconditioned through the housing membrane.
- The sensor includes a replaceable or renewable energy source selected from one or more replaceable batteries or a self generating system which uses a process such as motion or vascular flow, body heat, or chemical reaction.
- These and other aspects of the biological sensor will be further described herein.
- For a better understanding of the invention, and to show how the same may be carried into effect, reference will now be made, by way of example, to the accompanying drawings, in which:
-
FIG. 1 is an illustration depicting a pelvis identifying a location site for implanting the sensor in accordance with the invention. -
FIG. 2 is a schematic diagram of the sensor in accordance with the invention. - Referring to
FIGS. 1 and 2 the intraosseous implantable biological sensor in accordance with the invention will now be described. Thesensor 10 broadly includes ahousing 12, one or moresensing units 14, acontrol unit 16 and an energy source 18. Thehousing 12 includes amembrane 20 thereon that allows replacement and/or replenishment of individual parts, such assensing units 14. An ancillary processing device/control unit 22 can also be utilized and may integrated into the sensor or positioned and used at a remote location. -
Sensor 10 may direct automated and semi automated treatment techniques such as closed, and partially closed loop infusions. The insertion into the marrow space allows measurement through small blood channels while allowing thesensor 10 to be fixed directly to tissue. In addition, thesensor 10 is embedded (implanted) so that the skin and subcutaneous tissues cover it allowing minimal external compromise. -
Sensing units 14 may include optical, enzymatic, calorimetry, thermal, spectroscopy, or “lab on a chip.” A portion of thesensing units 14 are housed within the sensor housing and a portion thereof may project into thebone marrow 26 of a patient. Alternatively, the distal end of the sensing units may be flush with thehousing 12 but housing may contain an opening 30 that exposes the sensing units to the bone marrow These may be in a combined modality and other non specified technologies may also be used. The device may measure one or more analytes over various time cycles. These may be fixed or controlled externally by a wireless method to adjust the timing of thesensor 10. -
Control unit 16 may include a receiver for receiving a signal from the sensing units that includes physiological data of the patient. Thecontrol unit 16 may also includes a transmitter that may transmit the signal to a remotely located ancillary processing device 22 for analysis. The processing device 22 may include a display screen for displaying the analyzed data to monitor the condition of the patient. Data generated from thesensing units 14 may alter treatment settings of respirators, dialysis systems, pacemakers, defibrillators and intravenous, intraarterial, interstitial, cerebrospinal and subcutaneous injections and infusions as well as alteration and adjustment of other medical devices or treatments.Control unit 16 may include memory having a data base of knowledge including known normative data related to interpreting the analyte data received from the sensing units.Control unit 16 receives a signal from the sensing units which contains patient physiological parameters and analyzes the physiological parameters and other data obtained from thesensing units 14.Control unit 16 analyzes the data (i) in isolation as it is received; (ii) in the context of measurement and analysis based on the past history of the patient, which is stored in memory; or (iii) cross-references the patient data in the signal and cross-references it with the known normative data in the database. Alternatively,control unit 16 transmit the signal to a remotely located ancillary processing/control unit 22. The processing unit 22 optionally includes adisplay device 24 for displaying the output. Thecontrol unit 16 or the ancillary processing unit 22 can also include information related to goal-directed therapies associated with particular disease states for providing suggested goal-directed treatments based on the cross-referencing step and outputs a suggested treatment by transmitting it wirelessly or by wire to atreatment system 28. Thetreatment system 28 may include one or more medications for delivering the medications to a patient. - In addition the
sensing units 14 could monitor potentially toxic substances such as inhalants or injurious materials allowing rapid treatment, for example antidotes. Such treatment could be integrated with a separate embedded structure and could be initiated by a signal from the sensor. This treatment component could be embedded in themarrow 26 or another part of the body. - Energy source 18 may include one or more replaceable batteries or a self generating system which uses a process such as motion or vascular flow, body heat, or chemical reaction. These in combination with other sources known to those of skill in the art may also be used.
- The
sensor 10 is configured to measure and record numerous analytes including but not limited to biochemical, hormonal, inflammatory, hematologic, genetic/nucleic acid and physiologic concentrations, vascular pressures, flow rates, pharmacologic concentrations, degradation products, pH, oxygen, carbon dioxide, toxic exposures, metabolic factors such as glucose, lactate, electrolytes; hormones such as cortisol, insulin, epinephrine; drug and drug metabolites; other therapeutic substances such as monoclonal antibodies, ligands, and chemotherapeutic agents; hematologically active substances such coagulants and anticoagulants; DNA, RNA and nucleic acid containing substances. - The
sensor 10 may be implanted by surgical insertion and remain without extension through the skin. The area of implantation is pelvic and usually the ileum but not restricted to these sites. Thehousing 12 may comprise biologically inert or biocompatible material such as polymers, stainless steel, silicone and the like. Thehousing membrane 20 is porous so as to allow contact with the marrow circulation without producing inflammation and/or rejection. Regeneration of thesensing units 14 could be through injection or insertion of new material through temporary use of a catheter or needle into the device or alternatively extraction of the sensing units and replacement such as in a self contained form. Those of skill in the art will also appreciate that although long-term use is contemplated the entire sensor may be replaced or individual parts such as the energy source 18 orcontrol unit 16 may be replaced or replenished. - While the invention has been described with reference to the specific embodiments thereof, those skilled in the art will be able to make various modifications to the described embodiments of the invention without departing from the true spirit and scope of the invention. The terms and descriptions used herein are set forth by way of illustration only and are not meant as limitations. Those skilled in the art will recognize that these and other variations are possible within the spirit and scope of the invention as defined in the following claims and their equivalents.
Claims (11)
1. A sensor for measuring analytes comprising:
a housing having an interior;
a housing control unit positioned within the housing and having a transmitter and a receiver;
an energy source positioned within the housing for providing energy to the control unit;
one or more sensing units positioned at least partially within the housing and extending from the housing into a bone marrow of a patient, the sensing units in communication with the control unit;
a porous membrane covering a part of the housing that is configured to allow access to the interior of the housing.
2. The sensor of claim 1 further comprising an ancillary control unit located remotely from the sensor and in communication with the housing control unit, the ancillary control unit having a display.
3. The sensor of claim 2 wherein a signal from the one or more sensing units is received by the housing control unit and transmitted to the ancillary control unit.
4. The sensor of claim 3 wherein said signal transmitted to the ancillary control unit includes patient data that may be displayed on the display.
5. The sensor of claim 1 wherein the control unit is configured to receive a signal from the at least one or more sensing units, said signal including patient analyte data and transmit instructions to said at least one or more sensing units to measure analytes data on a fixed or adjustable schedule.
6. The sensor of claim 1 wherein the one or more sensing units are removable and replaceable.
7. The sensor of claim 1 further comprising a treatment system for providing medication to the patient, the treatment system housed within the housing or located remotely from a site where the sensor is implanted.
8. The sensor of claim 7 wherein the control unit is configured to receive a signal from the at least one or more sensing units, said signal including patient analyte data and transmit instructions to the treatment system to deliver medication to the patient based on the patient analyte data included in the at least one or more sensing units signal.
9. The sensor of claim 1 wherein the energy source is selected from one or more replaceable batteries or a self generating system which uses a process such as motion or vascular flow, body heat, or chemical reaction.
10. The sensor of claim 1 wherein the analytes are selected from biochemical, hormonal, inflammatory, hematologic, genetic/nucleic acid and physiologic concentrations, vascular pressures, flow rates, pharmacologic concentrations, degradation products, pH, oxygen, carbon dioxide, toxic exposures, metabolic factors such as glucose, lactate, electrolytes; hormones such as cortisol, insulin, epinephrine; drug and drug metabolites; other therapeutic substances such as monoclonal antibodies, ligands, and chemotherapeutic agents; hematologically active substances such coagulants and anticoagulants; DNA, RNA and nucleic acid containing substances.
11. The sensor of claim 1 wherein the sensor is implantable in a pelvic region of a patient.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/806,420 US20230131362A1 (en) | 2018-03-12 | 2022-06-10 | Intraosseous implanted biological sensor |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862641737P | 2018-03-12 | 2018-03-12 | |
PCT/US2019/021559 WO2019177938A1 (en) | 2018-03-12 | 2019-03-11 | Intraosseous implantable biological sensor |
US202016976104A | 2020-08-27 | 2020-08-27 | |
US17/806,420 US20230131362A1 (en) | 2018-03-12 | 2022-06-10 | Intraosseous implanted biological sensor |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/976,104 Continuation US11357425B2 (en) | 2018-03-12 | 2019-03-11 | Intraosseous implanted biological sensor |
PCT/US2019/021559 Continuation WO2019177938A1 (en) | 2018-03-12 | 2019-03-11 | Intraosseous implantable biological sensor |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230131362A1 true US20230131362A1 (en) | 2023-04-27 |
Family
ID=67907263
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/976,104 Active US11357425B2 (en) | 2018-03-12 | 2019-03-11 | Intraosseous implanted biological sensor |
US17/806,420 Pending US20230131362A1 (en) | 2018-03-12 | 2022-06-10 | Intraosseous implanted biological sensor |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/976,104 Active US11357425B2 (en) | 2018-03-12 | 2019-03-11 | Intraosseous implanted biological sensor |
Country Status (2)
Country | Link |
---|---|
US (2) | US11357425B2 (en) |
WO (1) | WO2019177938A1 (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100145317A1 (en) * | 2007-04-19 | 2010-06-10 | Morris Laster | Device system and method for monitoring and controlling blood analyte levels |
US20160212783A1 (en) * | 2015-01-21 | 2016-07-21 | Dexcom, Inc. | Continuous glucose monitor communication with multiple display devices |
US20160331284A1 (en) * | 2015-05-14 | 2016-11-17 | Abbott Diabetes Care Inc. | Compact medical device inserters and related systems and methods |
US9974483B2 (en) * | 2014-02-18 | 2018-05-22 | Ki Bong HYUN | Non-invasive blood measuring device |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6402689B1 (en) | 1998-09-30 | 2002-06-11 | Sicel Technologies, Inc. | Methods, systems, and associated implantable devices for dynamic monitoring of physiological and biological properties of tumors |
WO2003034902A2 (en) | 2001-10-23 | 2003-05-01 | Medtronic Minimed Inc. | Method and system for non-vascular sensor implantation |
US8080003B1 (en) * | 2006-02-02 | 2011-12-20 | Paunceforte Technologies, LLC | Method and implantable apparatus for the intra-osseal monitoring of biological substances in the bone marrow |
US8685093B2 (en) * | 2009-01-23 | 2014-04-01 | Warsaw Orthopedic, Inc. | Methods and systems for diagnosing, treating, or tracking spinal disorders |
-
2019
- 2019-03-11 WO PCT/US2019/021559 patent/WO2019177938A1/en active Application Filing
- 2019-03-11 US US16/976,104 patent/US11357425B2/en active Active
-
2022
- 2022-06-10 US US17/806,420 patent/US20230131362A1/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100145317A1 (en) * | 2007-04-19 | 2010-06-10 | Morris Laster | Device system and method for monitoring and controlling blood analyte levels |
US9974483B2 (en) * | 2014-02-18 | 2018-05-22 | Ki Bong HYUN | Non-invasive blood measuring device |
US20160212783A1 (en) * | 2015-01-21 | 2016-07-21 | Dexcom, Inc. | Continuous glucose monitor communication with multiple display devices |
US20160331284A1 (en) * | 2015-05-14 | 2016-11-17 | Abbott Diabetes Care Inc. | Compact medical device inserters and related systems and methods |
Also Published As
Publication number | Publication date |
---|---|
US20210038130A1 (en) | 2021-02-11 |
US11357425B2 (en) | 2022-06-14 |
WO2019177938A1 (en) | 2019-09-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6799149B2 (en) | Therapy management techniques for an implantable medical device | |
US7054782B2 (en) | Non-conformance monitoring and control techniques for an implantable medical device | |
US7018336B2 (en) | Implantable sensor flush sleeve | |
US8226556B2 (en) | Algorithm sensor augmented bolus estimator for semi-closed loop infusion system | |
US8303533B2 (en) | Device and method for delivery of a physiologically active substance depending on a measured physiological parameter | |
US7505869B2 (en) | Non-conformance monitoring and control techniques for an implantable medical device | |
EP1890588B1 (en) | Ambulatory medical device and method of communication between medical devices | |
US20030212379A1 (en) | Systems and methods for remotely controlling medication infusion and analyte monitoring | |
US20020087113A1 (en) | Drug management techniques for an implantable medical device | |
US20020087116A1 (en) | Patient scheduling techniques for an implantable medical device | |
CN102665535A (en) | Continuous non-interfering health monitoring and alert system | |
CN110868927B (en) | Maintaining maximum dose limits for closed-loop insulin management systems | |
US8080003B1 (en) | Method and implantable apparatus for the intra-osseal monitoring of biological substances in the bone marrow | |
US20230131362A1 (en) | Intraosseous implanted biological sensor | |
TW201832788A (en) | Audio bolus with improved safety for use in a drug delivery system | |
US20130079699A1 (en) | Method of draining autologous bodily fluid into intraosseus space |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |